Bayer, Thomas A.

Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer’s disease

Marlatt, M. W., Potter, M. C., Bayer, T. A., van Praag, H., & Lucassen, P. J. (2013) · Current Topics in Behavioral Neurosciences

Alzheimer's disease research and treatmentsNeurogenesis and neuroplasticity mechanisms

Cited by 92

Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease

Saul, A., Sprenger, F., Bayer, T. A., & Wirths, O. (2013) · Neurobiology of Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 88

APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy

Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 87

Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer’s disease

Pajonk, F.-G., Kessler, H., Supprian, T., Hamzei, P., Bach, D., Schweickhardt, J., Herrmann, W., Obeid, R., Simons, A., Falkai, P., et al. (2005) · Journal of Alzheimer's Disease

Trace Elements in HealthDementia and Cognitive Impairment Research

Cited by 83

Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease

Christensen, D. Z., Bayer, T. A., & Wirths, O. (2010) · Neurobiology of Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 77

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 61

Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

Kessler, H., Pajonk, F.-G., Bach, D., Schneider-Axmann, T., Falkai, P., Herrmann, W., Multhaup, G., Wiltfang, J., Schäfer, S., Wirths, O., et al. (2008) · Journal of Neural Transmission

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 61

Review on the APP/PS1KI mouse model: intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment

Bayer, T. A., & Wirths, O. (2008) · Genes, Brain and Behavior

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 60

N-truncated Abeta starting with position four: Early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody

Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 53

Formic acid is essential for immunohistochemical detection of aggregated intraneuronal Aβ peptides in mouse models of Alzheimer's disease

Christensen, D. Z., Bayer, T. A., & Wirths, O. (2009) · Brain Research

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 47

AβPP Accumulation and/or Intraneuronal Amyloid-β Accumulation? The 3xTg-AD Mouse Model Revisited

Wirths, O., Dins, A., & Bayer, T. A. (2012) · Journal of Alzheimer s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 26

Neuron Loss and Behavioral Deficits in the TBA42 Mouse Model Expressing N-Truncated Pyroglutamate Amyloid-β3–42

Meißner, J. N., Bouter, Y., & Bayer, T. A. (2015) · Journal of Alzheimer s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 16